Is Mobotinib succinate (Mobotinib) capsules a targeted drug?

Mobotinib succinate (moboxetinib) is a targeted drug. Mobosetinib succinate capsules are the world's first and only approved oral targeted drug for the treatment of advanced non-small cell lung cancer with EGFR exon 20 insertion mutations (EGFR exon20 Insertion+). Its emergence marks a major breakthrough in the treatment of this field. This drug is particularly suitable for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who carry epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed during or after platinum-containing chemotherapy.

EGFR exon 20 insertion mutation is a relatively rare gene mutation in non-small cell lung cancer, accounting for approximately 2.3% of all NSCLC in China. It is the third largest mutation in EGFR. Previously, there was a lack of effective targeted treatment options for this mutation. The approval of moboxetinib provides patients with a new treatment option and is of landmark significance.

Mobosetinib is an irreversible tyrosine kinase inhibitor targeting EGFRth 20 exon insertion mutation. It can specifically bind and inhibit mutated EGFR, thereby blocking the signal transduction of tumor cells and achieving the effect of inhibiting tumor growth and spread.

The drug has passed the priority review and approval process of the National Medical Products Administration and received conditional approval for marketing. This approval process reflects the Chinese drug regulatory authorities’ efficient review of innovative drugs and their emphasis on drugs urgently needed by patients.

Mobositinib succinate capsule, as an innovative targeted drug, provides a new treatment strategy for patients with advanced non-small cell lung cancer carrying EGFR 20 exon insertion mutations. Its unique targeting mechanism and significant therapeutic effect are expected to bring longer survival and better quality of life to such patients in clinical practice.